The latest market report published by Credence Research, Inc. “Opioid Induced Constipation (OIC) Drugs Market was valued at US$ 2,430.6 Mn in 2017, and is expected to reach US$ 3,770.4 Mn by 2026 expanding at a CAGR of 4.92% from 2018 to 2026.
The purpose of the report is to illustrate the state of the market of Opioid Induced Constipation (OIC) Drugs, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2016, and also, to build a forecast for the growth of the industry in the medium term until 2022.
Market Insights:
In the present scenario, drugs such as osmotic laxatives and stimulant cathartics which are prescribed by physicians during the initial treatment of opioid induced constipation are leading the drug type segment. Naloxegol will register significant growth owing to its enhanced drug safety and tolerability in comparison to other mu-receptor antagonists prescribed for opioid induced constipation.
Prescription drugs are currently dominating the global market due to increasing number of patients not gaining relief from opioid induced constipation from over the counter laxatives and stimulant cathartics. Over the counter products show therapeutic effect only in patients taking opioid analgesics for 3-4 weeks.
Leading Players:
The key players pioneering in the opioid induced constipation drugs market are AstraZeneca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer, Inc., Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Shionogo & Co Ltd., Sucampo Pharmaceuticals, Inc., and Synergy Pharmaceuticals, Inc.
Browse here for full report with Toc: https://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Opioid Induced Constipation (OIC) Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
Browse here for full report with Toc: https://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Opioid Induced Constipation (OIC) Drugs contains:
Analysis and forecast of Opioid Induced Constipation (OIC) Drugs market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Opioid Induced Constipation (OIC) Drugs market;
Assessment and forecast of Opioid Induced Constipation (OIC) Drugs market development;
Financial and business profiles of the leading companies in the Opioid Induced Constipation (OIC) Drugs industry.
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/57737
Scope
– Up to date working Opioid Induced Constipation (OIC) Drugs data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Opioid Induced Constipation (OIC) Drugs for the period 2018 to 2026
– Planned Opioid Induced Constipation (OIC) Drugs additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Opioid Induced Constipation (OIC) Drugs projects by region, key countries, and companies
– Details of major planned Opioid Induced Constipation (OIC) Drugs projects in the world up to 2026
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Contact Us:
Credence Research Inc.
105 N 1st ST #429
SAN JOSE
CA 95103
United States
Toll Free (US/CANADA): +1-800-361-8290